Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Lancet Gastroenterol Hepatol. 2021 Sep 21:S2468-1253(21)00300-9. doi: 10.1016/S2468-1253(21)00300-9.

in cat NOT

Stay Connected

Would you like to receive updates from ProSciento?